Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840464 | 0.79 | ADRB1 (0.45) | SLC6A3 | |
| SCHEMBL631423 | 0.79 | CYP3A4 (0.35) | SLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL7310726 | 0.79 | IDO1 (0.39) | SLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL5202527 | 0.75 | ENPP2 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7221676 | 0.75 | ALDH1A1 (0.36) | — | |
| SCHEMBL4380249 | 0.75 | PNMT (0.36) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8344764 | 0.75 | TP53 (0.40) | — | |
| SCHEMBL481290 | 0.75 | ALDH1A1 (0.36) | CRHBPCRHR2 | |
| SCHEMBL2852048 | 0.74 | CYP1A2 (0.45) | — | |
| SCHEMBL4502129 | 0.73 | TAAR1 (0.45) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | SLC6A2 1014/4885SLC6A4 861/4885SLC6A3 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.